居家肺康复对新冠后综合征患者运动能力的影响:一项随机对照试验
结果显示康复组在Chalder疲劳指数、6分钟步行试验、体能指数、SF-36问卷及mMRC呼吸困难评分上均显著优于对照组,提示居家肺康复有效且低成本,可作为辅助治疗。
要点
- 居家肺康复联合常规医疗可显著改善新冠后综合征患者的运动能力。
- 干预12周后康复组疲劳、呼吸困难及生活质量均显著优于对照组。
- 居家肺康复可作为新冠后综合征低成本、可推广的辅助疗法。
核心结论
- 居家肺康复对新冠后综合征患者在运动能力、疲劳、呼吸困难和生活质量方面有效。
- 居家肺康复可被视为一种辅助性、适用且低成本的疗法。
研究设计与样本
- 患者随机分为两组,对照组仅接受常规医疗,康复组接受居家肺康复运动方案加常规医疗。
- 干预前后(12周)测量体能指数、Chalder疲劳指数、SF-36问卷、呼吸困难量表和6分钟步行试验。
主要发现
- 康复组Chalder疲劳均值显著更低(11.1 ± 0.94)。
- 康复组6分钟步行试验均值更高(439.7 ± 25.3)。
- 康复组体能指数均值更高(52.3 ± 10.2)。
- 康复组SF-36问卷均值更高(66.4 ± 3.7)。
- 康复组mMRC呼吸困难评分显著改善:2级26.7%、1级63.3%、0级10%,P值<0.001。
临床怎么用
- 对新冠后综合征伴疲劳、呼吸困难和运动不耐受的患者,可在常规医疗基础上加用居家肺康复。
- 可采用Chalder疲劳指数、6分钟步行试验、体能指数、SF-36和mMRC评分进行干预前后评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Coronavirus 2019 (COVID-19) is an epidemic condition that compromises various consequences. The goal of this study was to investigate the effect of home-based pulmonary rehabilitation on exercise capacity in patients with post COVID-19 syndrome. METHODS: The study was designed as a randomized control trial. A total of sixty-eight patients with post COVID-19 syndrome complaining of fatigue, dyspnea, and exercise intolerance participated in this study. Their ages ranged from 40 to 70 years old. The patients were randomly classified into two equal groups. The control group received usual medical care only, whereas the rehabilitation group received a selected home-based pulmonary rehabilitation exercise program plus the same usual medical care. The Physical Fitness Index (PFI), Chalder fatigue index, SF-36 questionnaire, dyspnea scale, and six-minute walk test (6 MWT) were measured before and after 12 weeks of intervention. RESULTS: The rehabilitation group showed a significant lower mean of Chalder fatigue (11.1 ± 0.94) and a higher mean of 6MWT (439.7 ± 25.3) and PFI (52.3 ± 10.2), in addition to a higher mean of the SF-36 Questionnaire (66.4 ± 3.7) and a significant improvement of dyspnea in the mMRC score (26.7%), grade 2, (63.3%), grade 1 (10%), and grade 0 with a p-value < 0.001 when compared to the control group. CONCLUSION: Home-based pulmonary rehabilitation (HBPR) for patients with post COVID-19 syndrome is effective and has a potential direct influence on exercise capacity, fatigue, dyspnea, and quality of life. HBPR could be considered an adjunctive, applicable, and low-cost therapy for patients with post COVID-19 syndrome. TRIAL REGISTRATION: The study was registered in Pan African Clinical Trial Registry as a clinical trial ID (PACTR202111640499636), November 2021.
引用
- Elyazed TIA, Alsharawy LA, Salem SE, et al. Effect of home-based pulmonary rehabilitation on exercise capacity in post COVID-19 patients: a randomized controlled trail. J Neuroeng Rehabil. 2024. PMID: 38528512. doi:10.1186/s12984-024-01340-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。